UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION

<p>Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The resul...

Full description

Bibliographic Details
Main Authors: E. A. Protasova, N. V. Furman, O. V. Reshet'ko
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/501
id doaj-3f2f3caecf624deaaff7a092a0b463e4
record_format Article
spelling doaj-3f2f3caecf624deaaff7a092a0b463e42020-11-24T22:37:15ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-12-018456156810.1234/1819-6446-2012-4-561-568501UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTIONE. A. Protasova0N. V. Furman1O. V. Reshet'ko2Саратовский научно-исследовательский институт кардиологииСаратовский научно-исследовательский институт кардиологииСаратовский государственный медицинский университет им. В.И. Разумовского<p>Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The results of experiments and clinical studies show that the use of these drugs may be useful for AF primary prevention in certain categories of patients. Nevertheless, there are currently no sufficient evidences to justify these recommendations and apply them to a wider range of patients with AF risk factors. Thus, it is reasonable to continue studies on both primary and secondary AF prevention.</p>http://www.rpcardio.ru/jour/article/view/501фибрилляция предсердийпрофилактика
collection DOAJ
language English
format Article
sources DOAJ
author E. A. Protasova
N. V. Furman
O. V. Reshet'ko
spellingShingle E. A. Protasova
N. V. Furman
O. V. Reshet'ko
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
Racionalʹnaâ Farmakoterapiâ v Kardiologii
фибрилляция предсердий
профилактика
author_facet E. A. Protasova
N. V. Furman
O. V. Reshet'ko
author_sort E. A. Protasova
title UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
title_short UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
title_full UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
title_fullStr UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
title_full_unstemmed UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
title_sort up to day possibilities of atrial fibrillation prevention
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2015-12-01
description <p>Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The results of experiments and clinical studies show that the use of these drugs may be useful for AF primary prevention in certain categories of patients. Nevertheless, there are currently no sufficient evidences to justify these recommendations and apply them to a wider range of patients with AF risk factors. Thus, it is reasonable to continue studies on both primary and secondary AF prevention.</p>
topic фибрилляция предсердий
профилактика
url http://www.rpcardio.ru/jour/article/view/501
work_keys_str_mv AT eaprotasova uptodaypossibilitiesofatrialfibrillationprevention
AT nvfurman uptodaypossibilitiesofatrialfibrillationprevention
AT ovreshetko uptodaypossibilitiesofatrialfibrillationprevention
_version_ 1725717974006890496